Download presentation
Presentation is loading. Please wait.
Published byRose Webster Modified over 9 years ago
1
Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D. May 27, 2011
2
Rationale Perform OMICs of healthy, polyps, cancer Perform OMICs of healthy, polyps, cancer Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers
3
Schema IUCRO-0221 CCE in CRC SAMPLESSAMPLES Blood (Serum) 7 mL red top Metabolomics, vit D Blood (Plasma) 21 mL purple top Genomics, lipidomics, glycoproteomics N=810 Stratification: -Healthy (n=270) -Polyps (n=270) -Cancer (n=270) stg 1/2 stg 3 stg 4 metastatic Fresh Tissue 10 mg polyp or 50 mg cancer / 50 mg normal tissue SHIPDRYICESHIPDRYICE 8-hr fasting Paraffin-Embedded Tissue MSI, methylation, KRAS, BRAF, p53
4
Samples Collection Healthy Controls Screening Colonoscopy – GI Clinic Label specimens Healthy if no polyps/tumor Blood Questionnaires N= 5 6/2009 N=74 5/2010 N=109 5/2011
5
Samples Collection Adenomatous Polyps Screening Colonoscopy – GI Clinic Label specimens Polyp Polyps identified Tissue procurement/Research specialist -Polyp cut in ½ -Place in tube with no preservative -Freeze at -70 o C Blood Questionnaires N= 3 6/2009 N= 65 5/2010 N= 96 5/2011
6
Samples Collection Cancer Surgery Tissue: tumor, normal mucosa Blood Questionnaires ChemotherapyFollow-up Every 3 months Up to 24 months N= 8 6/2009 N= 34 5/2010 N= 55 5/2011
7
Sample Acquisition 4/2009-5/2011 Cancer total No prior chemo Prior chemo n=55 n=26 n=29 Stage 1 n=6 n=6 0 Stage 2 n=3 n=2 n=1 Stage 3 n=17 n=10 n=7 Stage 4 n=29 n=8 n=21
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.